GleamWall
中文EN

AGEN AGENUS INC

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1098972 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY25.4%
TTM net income YoY187.7%
TTM EPS YoY114.6%
Revenue 3-yr CAGR9.9%
Net income 3-yr CAGR—

Margins

Gross margin100.0%
Operating margin38.9%
Net margin23.0%
FCF margin-77.5%
EBITDA margin40.6%

Returns

ROE—
ROA12.9%
ROIC (approx.)—
Asset turnover0.56x

Leverage & solvency

Liabilities / assets145.7%
Debt / equity—
Current ratio0.73x
Interest coverage0.85x

Cash quality & payout

Operating cash flow / net income-3.37x
Accruals ratio56.2%
Payout ratio—
Capex / revenue0.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY2025*2025-12-31FY2024*2024-12-31
Income statement
Revenue$114.20M$103.46M
Cost of revenue$1.02M$486,000
Gross profit$113.17M$102.98M
R&D expense$79.34M$155.53M
SG&A expense$54.39M$71.88M
Operating income-$20.17M-$120.47M
Interest expense$55.62M$120.42M
Pretax income-$3.08M-$232.27M
Income tax$0$0
Net income$115,000-$227.21M
EBITDA-$10.17M-$107.13M
EPS (basic)0.00-10.59
EPS (diluted)0.00-10.59
Weighted avg. shares (diluted)29.73M21.47M
Balance sheet
Cash & equivalents$3.00M$40.44M
Short-term investments$0—
Receivables$1.83M$407,000
Current assets$133.44M$45.57M
PP&E, net$15.47M$120.09M
Goodwill$24.09M$24.09M
Intangibles$3.04M$3.38M
Total assets$226.80M$226.27M
Current liabilities$323.49M$221.40M
Short-term debt$44.66M$2.70M
Long-term debt$0$30.47M
Total debt$44.66M$33.17M
Total liabilities$504.66M$532.70M
Shareholders' equity-$271.11M-$326.38M
Net debt$41.66M-$7.27M
Shares outstanding35.32M23.63M
Cash flow statement
Operating cash flow-$77.19M-$158.31M
Capital expenditure$6,000$576,000
Free cash flow-$77.20M-$158.89M
Investing cash flow$1.19M$27,000
Financing cash flow$36.59M$122.84M
Depreciation & amortization$10.00M$13.34M
Stock-based compensation$13.77M$17.39M

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.